摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-methylbenzo[b]thiophene-3-carboxylic acid | 17375-82-5

中文名称
——
中文别名
——
英文名称
2-methylbenzo[b]thiophene-3-carboxylic acid
英文别名
2-Methyl-1-benzothiophene-3-carboxylic acid
2-methylbenzo[b]thiophene-3-carboxylic acid化学式
CAS
17375-82-5
化学式
C10H8O2S
mdl
——
分子量
192.238
InChiKey
AFUYTLSLJWHYSV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    195.8-196.4 °C
  • 沸点:
    379.9±22.0 °C(Predicted)
  • 密度:
    1.355±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.9
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.1
  • 拓扑面积:
    65.5
  • 氢给体数:
    1
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    2-(Quinuclidin-3-yl)pyrido[4,3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists
    摘要:
    Several series of N-(quinuclidin-3-yl)aryl and heteroaryl-fused pyridones were synthesized and evaluated for 5-HT3 receptor affinity. In the heteroaryl series, 2-(quinuclidin-3-yl)tetrahydropyrido-[4,3-b]indol-1-one (8a) and the 4,5-alkano-bridged analogues (14 and 15) displayed high 5-HT3 receptor affinity with pK(i) values > 9. The (3S)-quinuclidinyl isomers had > 10 fold higher affinity than the (3R)-isomers. In a series of 2-quinuclidin-3-yl)isoquinolin-1-ones, derivatives substituted with small lipophilic groups (25b-e) and with 4,5-alkano-bridges (34-36) also displayed high affinity. In particular, the hexahydro-1H-benz[de]isoquinolinone (S,S)-37 was the highest affinity 5-HT3 receptor ligand prepared (pK(i) 10.4). A number of the high affinity ligands were shown to be potent 5-HT3 receptor antagonists in vivo as determined by inhibition of the B-J reflex in the anesthetized rat. Again, (S,S)-37 was the most active agent tested (ID50 0.02 mug/kg iv), and this compound was also potent in blocking cisplatin-induced emesis in both the ferret and the dog. Computer modeling studies were performed, and previously reported 5-HT3 receptor antagonist pharmacophore models were refined to include a key lipophilic binding domain.
    DOI:
    10.1021/jm00070a008
  • 作为产物:
    参考文献:
    名称:
    Substitution Reactions of 2- and 3-Methylthianaphthene
    摘要:
    DOI:
    10.1021/ja01109a512
点击查看最新优质反应信息

文献信息

  • ACETYL CoA CARBOXYLASE INHIBITORS
    申请人:Chang Edcon
    公开号:US20090253725A1
    公开(公告)日:2009-10-08
    The present invention relates to acetyl coenzyme-A carboxylase (“ACC”) inhibiting compounds of the formula wherein the variables are as defined herein. In particular, the present invention relates to ACC1 and/or ACC2 inhibitors, compositions of matter, kits and articles of manufacture comprising these compounds, methods for inhibiting ACC1 and/or ACC2, and methods of making the inhibitors.
    本发明涉及乙酰辅酶A羧化酶(“ACC”)抑制化合物,其化学式如下 其中变量如本文所述定义。特别是,本发明涉及ACC1和/或ACC2抑制剂,包含这些化合物的物质、套件和制品,抑制ACC1和/或ACC2的方法,以及制造抑制剂的方法。
  • [EN] COMPOUNDS HAVING ACTIVITY AT 5HT2C RECEPTOR AND USES THEREOF<br/>[FR] COMPOSES AYANT UNE ACTIVITE AU NIVEAU DU RECEPTEUR 5HT2C ET LEURS UTILISATIONS
    申请人:GLAXO GROUP LTD
    公开号:WO2004081010A1
    公开(公告)日:2004-09-23
    Compounds of formula (I) and pharmaceutically acceptable salts thereof are disclosed: wherein Q is phenyl or a 6-membered heteroaromatic group containing at least one nitrogen atom; A is -(CH2-CH2)-, -(CH=CH)-, -(CH2)3-, -C(CH3)2-, -(CH=CH-CH2)-, or a group -(CHR3)- wherein R3 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy or C1-6alkylthio; B is O, S or NR11, wherein R11 is hydrogen, C1-6alkyl optionally substituted by C1-6alkoxy, or is C1-6alkanoyl optionally substituted by C1-6alkoxy; R1 is halogen, cyano, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyloxy, C1-6alkoxy, C1-6alkylthio, hydroxy, amino, mono- or di-C1- 6alkylamino, an N-linked 4 to 7 membered heterocyclic group, nitro, haloC1-6alkyl, haloC1-6alkoxy, aryl, arylC1-6alkyl, arylC1-6alkyloxy, arylC1-6alkylthio, COR4 (wherein R4 is amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group), COOR5 or COR6 (wherein R5 and R6 are independently hydrogen or C1-6alkyl); p is 0, 1 or 2 or 3; R2 is hydrogen, halogen, hydroxy, cyano, nitro, C1-6alkyl, C1-6alkanoyl, C3-7cycloalkyl, C3-7cycloalkyloxy, haloC1-6alkyl, C1-6alkoxy, haloC1-6alkoxy, C1-6alkylthio, amino, mono- or di-C1-6alkylamino or an N-linked 4 to 7 membered heterocyclic group; X is oxygen, sulfur, -CH2- or NR8 wherein R8 is hydrogen or C1-6alkyl; Y is a single bond, -CH2-, -(CH2)2- or -CH=CH-; and Z is an optionally substituted N-linked heterocyclic group or a C-linked 4 to 7 membered heterocyclic group containing at least one nitrogen, or Z is -NR9R10 where R9 and R10 are independently hydrogen or C1-6alkyl. Method of preparation and uses thereof in therapy, such as for example in treatment of depression and anxiety, are also disclosed.
    公开了具有式(I)的化合物及其药学上可接受的盐:其中Q是苯或含有至少一个氮原子的6元杂芳基团;A是-(CH2-CH2)-,-(CH=CH)-,-(CH2)3-,-C(CH3)2-,-(CH=CH-CH2)-,或一个-(CHR3)-基团,其中R3是氢,卤素,羟基,氰基,硝基,C1-6烷基,C3-7环烷基,C3-7环烷氧基,卤代C1-6烷基,C1-6烷氧基,卤代C1-6烷氧基或C1-6烷基硫基;B是O,S或NR11,其中R11是氢,C1-6烷基,可选择地被C1-6烷氧基取代,或是C1-6烷酰基,可选择地被C1-6烷氧基取代;R1是卤素,氰基,C1-6烷基,C3-7环烷基,C3-7环烷氧基,C1-6烷氧基,C1-6烷基硫基,羟基,氨基,单或双C1-6烷基氨基,N-连接的4到7成员杂环基团,硝基,卤代C1-6烷基,卤代C1-6烷氧基,芳基,芳基C1-6烷基,芳基C1-6烷氧基,芳基C1-6烷硫基,COR4(其中R4是氨基,单或双C1-6烷基氨基或N-连接的4到7成员杂环基团),COOR5或COR6(其中R5和R6独立地是氢或C1-6烷基);p是0,1,2或3;R2是氢,卤素,羟基,氰基,硝基,C1-6烷基,C1-6烷酰基,C3-7环烷基,C3-7环烷氧基,卤代C1-6烷基,C1-6烷氧基,卤代C1-6烷氧基,C1-6烷基硫基,氨基,单或双C1-6烷基氨基或N-连接的4到7成员杂环基团;X是氧,硫,-CH2-或NR8,其中R8是氢或C1-6烷基;Y是单键,-CH2-,-(CH2)2-或-CH=CH-;Z是一个可选择地取代的N-连接杂环基团或含有至少一个氮的C-连接的4到7成员杂环基团,或Z是-NR9R10,其中R9和R10独立地是氢或C1-6烷基。还公开了其制备方法及在治疗中的用途,例如在抑郁症和焦虑症的治疗中。
  • AZETIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS
    申请人:Aissaoui Hamed
    公开号:US20100222600A1
    公开(公告)日:2010-09-02
    The invention relates to novel azetidine compounds of formula (I), wherein R 1 , R 2 , and X are as described in the description and their use as orexin receptor antagonists.
    这项发明涉及一种新型的式(I)的氮杂环丙烷化合物,其中R1、R2和X如描述中所述,并且它们作为促进睡眠的药物受体拮抗剂的用途。
  • [EN] AMINOACYLINDAZOLE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES<br/>[FR] IMMUNOMODULATEURS À BASE D'AMINOCYLINDAZOLE POUR LE TRAITEMENT DE MALADIES AUTO-IMMUNES
    申请人:UNIV ROCKEFELLER
    公开号:WO2017205296A1
    公开(公告)日:2017-11-30
    2-Acylindazole compounds of formula I or formula II are disclosed. These compounds inhibit Coagulation Factor XIIa. They are useful to treat autoimmune diseases.
    公开了式I或式II的2-酰基吲唑化合物。这些化合物抑制凝血因子XIIa。它们可用于治疗自身免疫疾病。
  • Direct Carboxylation of Thiophenes and Benzothiophenes with the Aid of EtAlCl<sub>2</sub>
    作者:Koji Nemoto、Satoru Onozawa、Megumi Konno、Naoya Morohashi、Tetsutaro Hattori
    DOI:10.1246/bcsj.20110335
    日期:2012.3.15
    Thiophenes and benzothiophenes bearing alkyl or aryl substituents at the 2- or 3-positions are successfully carboxylated with CO2 with aid of EtAlCl2 to give the corresponding 2- or 3-carboxylic acids in up to 90% yield.
    含有在2位或3位具有烷基或芳基取代基的噻吩和苯并噻吩,经过乙基铝氯的辅助,成功地与二氧化碳进行羧化反应,得到相应的2位或3位羧酸,产率高达90%。
查看更多

同类化合物